/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Biological products, (no diagnostic substances) company · FY ends Dec · -$141M FCF
$21.40
$0.49 (-2.24%)
EOD Sep 18, 2026
ROIC dropped from -60.81% to -446.56%, capital efficiency is deteriorating. Negative free cash flow of -$144M. The business is consuming cash, not generating it.
0.1x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
$628M
▼ -495.3% YoY
Op. Margin
—
ROIC
-3913.88%
▼ -385.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$141M
▼ -43.8% YoY
Op. Cash Flow (TTM)
-$140M
▼ -43.2% YoY
Net Debt
-$463M
Net Cash Position
Cash & Equiv.
$466M
Continue Research
SourceComputed from the 10-Q filed 11 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 0.1, Vor Biopharma (VOR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
That depends on valuation and quality together, not either alone. you should weigh VOR's valuation. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.